B. Purpose of the requirement, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency

The new requirement was implemented in UK legislation in order to:

1. Enhance the safety of trial subjects/patients by seeking to ensure that the licensing authority is promptly informed of such serious breaches, in order to take appropriate action in response to the breach and/or,

2. To take the information regarding serious breaches into account when assessing future applications for clinical trial authorisation, and applications for marketing authorisation, which include data from trials affected by serious breaches.

 

Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency.

Clinical Research News

Beyond Oral Pills: Can a Once-Daily Inhaler Slow Progressive Lung Scarring?
From cancer to Alzheimer’s: nine medical advances and trials to watch now
Can Two Pills Beat Chemotherapy? Targeted Combination for Pancreatic Cancer Enters Phase 3
GSK Moves mRNA Flu Vaccine Into 54,000-Person Phase 3 Trial in Adults 65 and Older
The End of Weight-Loss Injections? AstraZeneca’s Daily Pill Enters Phase III Trials
Can a Once-Weekly Weight-Loss Injection Also Reduce Sleep Apnea? Phase III Trials Begin
Algorithm vs. Stroke: Can AI Catch the "Golden Window" for Intravenous Thrombolysis?

Upcoming Clinical Trials

Clinical Research Jobs

More jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Subscribe